It has recently been described that many commercial methods for the determination of plasmin inhibitor (PI) activity are not specific at low plasmin inhibitor concentrations (1, 2). This non-specificity results in values of 10-30 % when analysing PI-deficient plasmas. We have now developed a sensitive method which meets the criteria for a specific PI- activity method (3). Low plasmin concentrations (< 0.3 nkat/mL) and short incubation times (< 60 s) are used in combination with the highly selective chromogenic plasmin substrate, S-2403. With methylamine included in the buffer, no significant interference is observed when adding alpha-2-macroglobulin in excess (9 μM) to a Pi-deficient plasma. The specificity was further investigated and no influence from the non-plasminogen binding form of plasmin inhibitor (0.3 μM) or EACA (< 4 mM) was observed. The resulting kit contains; plasmin, plasmin solvent, methylamine buffer and S-2403. The kit has been adapted for the ACL 300R, Cobas Mira, MLA Electra 1000C and the Thrombolyzer instrument beside microplate and manual procedures. All the instrumentspecific methods results in an activity of < 6 % when analysing either a commercially Pi-deficient plasma or plasma from a congenitally Pi-deficient individual. Conclusion: The new Coamatic Plasmin Inhibitor kit provides instrument-specific methods that meet the criteria for valid methods for the determination of plasmin inhibitor activity.